ICIs targeting programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are pivotal in countering the tumour-tolerant microenvironment in iCCA [71]. This evidence concerns the gene CD274 and neoplasm.